AMGN drug pipeline

The next hard catalyst is the Phase 3 MARITIME-1/2 topline readout, expected shortly after the estimated primary completion date of January 21, 2027. Positive data (confirming ~20% weight loss with monthly dosing and good tolerability) could drive significant upside as it validates Amgen's differentiated GIP-antagonist approach and monthly dosing advantage. Negative data (efficacy below competitors or tolerability issues) would be a major setback since Amgen has narrowed its obesity pipeline to MariTide alone. The stock already trades near 52-week highs with elevated options implied volatility (IV rank 76), suggesting the market is pricing in this binary event.

The OCEAN(a)-Outcomes topline readout expected around December 2026 is the single most important near-term catalyst for olpasiran. A positive result showing cardiovascular event reduction would validate the Lp(a) hypothesis after Novartis' pelacarsen failure and could unlock a multi-billion-dollar market, while a negative result would likely cast doubt on the entire drug class and weigh on Amgen shares. The stock's recent recovery to near 52-week highs and broad analyst price-target increases suggest some optimism, but the class-wide skepticism from the pelacarsen miss means the bar for proof is high.

The next catalyst is the OASIZ 303 Phase 3 topline readout, expected by end of Q4 2026 (any day now). A positive result would validate dazodalibep across both Sjögren's subpopulations (systemic and symptomatic), strengthening the case for a BLA filing. A negative or mixed readout would not kill the program (OASIZ 301 already succeeded) but would narrow the addressable label. Amgen has not yet disclosed a regulatory submission timeline; watch for that announcement after OASIZ 303 data.

ABP 938/Pavblu is already approved and generating $700M/year in sales, the binary approval event is behind it. For Amgen investors, Pavblu is a meaningful contributor to the $3B biosimilar segment (37% YoY growth) but only ~2% of total $36.8B revenue. Watch for H2 2026 competition entry from other aflibercept biosimilars that could erode Pavblu's current monopoly pricing. The next significant Amgen catalysts are other pipeline readouts (e.g., IMDELLTRA, UPLIZNA), not this drug.

BLINCYTO has no near-term binary catalyst. Watch for quarterly sales growth trends as a proxy for adoption into earlier treatment lines, and for any data updates on the subcutaneous formulation at 2027 medical conferences. The key long-term risk is the 2029 US exclusivity cliff, but that is more than two years away. For Amgen as a whole, BLINCYTO is a steady growth contributor within a much larger, diversified portfolio.

EVENITY has no near-term binary catalysts. The key metric to watch is its quarterly sales trajectory, which has been accelerating (39% growth in Q3 2026). Any slowdown in that growth rate or news about cardiovascular safety litigation would be the main bearish signals, while continued market share gains or a potential FDA label expansion to include men (already approved in Europe) would be bullish. The next scheduled update will be Amgen's Q4 2026 earnings, likely in early February 2027.

Watch for Amgen's announcement of a supplemental BLA submission to the FDA for first-line maintenance use of IMDELLTRA based on the DeLLphi-305 data. That submission would trigger a 6-10 month review cycle and a PDUFA date, creating a clear binary catalyst. Also monitor DeLLphi-306 enrollment updates for the limited-stage SCLC opportunity. IMDELLTRA's quarterly sales trajectory (currently doubling YoY) will be a key metric in Amgen's earnings reports.

KRYSTEXXA is a steady commercial growth story within Amgen's portfolio, but with no pending PDUFA or pivotal readout, there is no near-term binary catalyst for the stock. Watch for potential FDA supplemental filings for monthly (Q4W) dosing or shortened 60-minute infusion, which could incrementally expand the market. Also monitor Amgen's quarterly earnings for continued sales growth trajectory. The ACR Convergence 2026 real-world evidence presentations (November 2026) are informational, not stock-moving events.

Watch for the CodeBreaK 202 Phase 3 readout (sotorasib + chemo in first-line NSCLC), which could expand the addressable patient population significantly if positive. Also monitor how quickly Roche's divarasib, which beat LUMAKRAS head-to-head at ESMO 2026, gains regulatory approval and market share. Neither catalyst is imminent; LUMAKRAS is a slow-moving, modest contributor within Amgen's massive portfolio.

MVASI has no upcoming PDUFA, pivotal readout, or binary catalyst. The next scheduled event is Amgen's Q4 2026 earnings release (likely early February 2027), where MVASI's ongoing sales erosion from biosimilar competition and pricing pressure will be one data point among many in a diversified portfolio. For a non-medical investor, MVASI is a slow-moving, commoditized asset within a large-cap biotech; watch the broader bevacizumab biosimilar market ASP trends and Amgen's overall biosimilar franchise performance rather than this single drug.

Nplate has no hard, dated binary catalyst in the next 12 months. Watch for data from the ongoing Phase 3 CIT trial (NCT03937154, estimated completion May 2027) and for any FDA biosimilar approval or filing that could pressure the franchise. The Q3 2026 earnings showed steady 3% sales growth, and the drug remains a modest but stable contributor to Amgen's diversified revenue base.

Prolia has no upcoming regulatory catalysts; the stock-moving events are Amgen's quarterly earnings reports, where Prolia's sales trajectory and biosimilar market-share losses will be a key metric. The next quarterly report (Q4 2026 / full-year 2026) is due in early February 2027. Investors should watch whether Prolia's decline stabilizes as biosimilar competition matures, or accelerates as more biosimilars enter.

Repatha has no upcoming hard binary catalyst (PDUFA or pivotal readout) in the next 12 months; the October 9, 2026 FDA label expansion for VESALIUS-CV primary-prevention data is already past. Watch quarterly sales growth as a commercial-performance indicator, and monitor Novartis's ORION-4 cardiovascular outcomes readout for Leqvio (expected mid-2026 or later), which could shift the PCSK9 competitive landscape. Amgen's Q3 2026 earnings (reported November 3, 2026) showed Repatha sales of $1.085 billion, beating expectations.

The next catalyst is the FDA hearing on the proposed withdrawal of TAVNEOS approval. Amgen submitted its hearing request on July 23, 2026, but no hearing date has been publicly set. If the FDA ultimately withdraws approval, TAVNEOS revenue (about $105M/quarter, ~1% of Amgen's total) would be lost, but the impact on Amgen's diversified $250B market cap would be modest. A positive outcome preserving the drug would remove a regulatory overhang but is unlikely to materially move the stock given the drug's small revenue contribution.

UPLIZNA has no pending PDUFA or pivotal readout with a hard date in the next 12 months. Watch quarterly sales growth as a commercial barometer, and monitor the Phase 2 lupus data readout and the planned Phase 3 CIDP trial initiation for pipeline-expansion signals. The Zenas obexelimab PDUFA (May 2027) is a competitive overhang, though obexelimab's weaker efficacy data reduce the threat.

Vectibix is a mature, approved product with no upcoming PDUFA or pivotal readout. The FDA warning letter (Oct 27, 2026) over a promotional video is a compliance issue Amgen says stemmed from an inadvertent submission of an undisseminated file; it is unlikely to materially affect sales. Watch quarterly revenue trends for volume growth trajectory and any label-expansion data from ongoing PARADIGM/PRIME studies, though none are near-term binary catalysts.

The next catalyst for AMG 732 is the estimated primary completion of the Phase 1/2 study (NCT06401044) around January 6, 2027, which could yield topline safety and efficacy data. However, given Amgen's mega-cap size and deep pipeline, even positive data would have a negligible impact on AMGN shares. Investors should watch for any disclosure of Phase 1/2 results and whether Amgen advances the program to Phase 3, but the stock's thesis rests on far larger products (Tepezza, Enbrel, Prolia, Repatha, etc.).

AMJEVITA is a mature, approved biosimilar with no upcoming binary regulatory catalysts. The key metric to watch is quarterly global sales growth (Q3 2026: $191M, +24% YoY) and whether US sales can recover from the Q2 2026 trough of $19M. With 10 adalimumab biosimilars now approved, pricing pressure and market share dynamics will determine whether this product can sustain mid-single-digit revenue contribution for Amgen.

The next catalyst is the initiation and enrollment of Phase 3 registrational trials for discoid lupus, which Amgen has signaled it is preparing but has not yet announced a timeline for. A successful Phase 3 program could open a first-in-class treatment for DLE, a niche with no approved biologics, but the drug's prior failure in SLE and the small addressable DLE market limit the commercial upside for a company of Amgen's scale.

Kyprolis has no upcoming binary catalysts. Watch Amgen's quarterly earnings for the trajectory of Kyprolis sales declines versus the broader multiple myeloma market growth. The key risk is accelerating share loss to newer therapies (CAR-T, bispecifics, oral drugs). For Amgen investors, Kyprolis is a legacy headwind that is more than offset by growth in Repatha, UPLIZNA, TEZSPIRE, and the emerging MariTide obesity program.

No near-term binary catalyst exists for Otezla. The next major event is the February 2028 patent cliff when generic apremilast can enter the US market, which is well-telegraphed and roughly 15 months away. Watch quarterly sales trends for the pace of erosion and any Otezla XR extended-release uptake as a lifecycle management signal. For Amgen investors, Otezla's decline is one of many moving parts in a $39B+ revenue portfolio dominated by newer growth drivers like Repatha, Tezspire, and Imdelltra.

Watch for formal disclosure of LEVANTE Phase 2b results, which could inform whether the drug advances to Phase 3. Also monitor for the start of Phase 3 enrollment, which would signal continued commitment from Amgen and AstraZeneca. Given Amgen's size and diversified pipeline, sunakiment is unlikely to be a standalone catalyst for the stock in the near term.

Xaluritamig has no near-term binary catalyst. The two Phase 3 trials (XALience and XALute) are still recruiting with primary completion estimated around 2030. Watch for future Phase 1/2 data updates at medical conferences (ASCO, ESMO) and any signals on enrollment pace or early efficacy from the ongoing Phase 3 programs. For Amgen, this is one of many pipeline assets; the stock's near-term drivers are broader commercial performance and other pipeline readouts.